Karl Lewis
University of Colorado Denver
H-index: 59
North America-United States
Top articles of Karl Lewis
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Health-related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 open-label clinical trial | SKIN The Journal of Cutaneous Medicine | Karl D Lewis Timothy J Inocencio Ruben GW Quek Patrick R LaFontaine Zeynep Eroglu | 2024/1/16 |
A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis | Neuro-Oncology Advances | Alexander M Menzies Georgina V Long Amiee Kohn Hussein Tawbi Jeffrey Weber | 2024/3/18 |
A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced ccRCC. | Miso Kim Raymond S McDermott Stephen K Williamson Byoung Chul Cho Afshin Dowlati | 2024/2/1 | |
Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors | Annals of Oncology | KD Lewis K Peris A Sekulic AJ Stratigos L Dunn | 2024/2/1 |
Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up | Journal of the American Academy of Dermatology | Alexander J Stratigos Aleksandar Sekulic Ketty Peris Oliver Bechter Sorilla Prey | 2024/2/1 |
A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers | Cancer | Alain P Algazi James Moon Christopher D Lao Bartosz Chmielowski Kari L Kendra | 2024/1/23 |
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim … | The Lancet Oncology | Paolo A Ascierto Daniil Stroyakovskiy Helen Gogas Caroline Robert Karl Lewis | 2023/1/1 |
43001 Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis | Journal of the American Academy of Dermatology | Omid Hamid Amy Weise Karl D Lewis Tae Min Kim Meredith McKean | 2023/9/1 |
Phase 1 study of fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis | SKIN The Journal of Cutaneous Medicine | Omid Hamid Karl Lewis Amy Weise Meredith McKean Kyriakos P Papadopoulos | 2023/3/13 |
Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis. | Omid Hamid Karl D Lewis Amy M Weise Meredith McKean Kyriakos P Papadopoulos | 2023/6/1 | |
Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Long-term follow-up | SKIN The Journal of Cutaneous Medicine | Alexander J Stratigos Aleksandar Sekulic Ketty Peris Oliver Bechter Sorilla Prey | 2023/3/13 |
HSR23-097: Health-Related Quality of Life in Patients With Metastatic Basal Cell Carcinoma Treated With Cemiplimab: Analysis of a Phase 2 Open-Label Clinical Trial | Journal of the National Comprehensive Cancer Network | Karl D Lewis Timothy J Inocencio Ruben GW Quek Patrick R LaFontaine Zeynep Eroglu | 2023/3/31 |
Effectiveness of adjuvant pembrolizumab vs high-dose interferon or Ipilimumab for quality-of-life outcomes in patients with resected melanoma: a secondary analysis of the SWOG … | JAMA oncology | Joseph M Unger Amy Darke Megan Othus Thach-Giao Truong Nikhil Khushalani | 2023/2/1 |
Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors | SKIN The Journal of Cutaneous Medicine | Karl D Lewis Ketty Peris Aleksandar Sekulic Alexander J Stratigos Lara Dunn | 2023/3/13 |
Brief overview: Cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again | Christina M Davis Karl D Lewis | 2022/1 | |
Adjuvant pembrolizumab versus IFNα2b or ipilimumab in resected high-risk melanoma | Cancer discovery | Kenneth F Grossmann Megan Othus Sapna P Patel Ahmad A Tarhini Vernon K Sondak | 2022/3/1 |
Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive … | Grant A McArthur Ralf Gutzmer Daniil Stroyakovskiy Helen Gogas Caroline Robert | 2022/6/1 | |
813P Time to development of central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with vemurafenib (V)+ cobimetinib (C): Updated results … | Annals of Oncology | K Lewis C Robert R Ramella Munhoz G Liszkay L de la Cruz Merino | 2022/9/1 |
Navtemadlin (KRT-232) in combination with avelumab for patients with anti-PD-1/L1 treatment-naïve TP53WT Merkel cell carcinoma (MCC) | Journal of Investigative Dermatology | Michael K Wong Melissa Burgess Sunandana Chandra Dirk Schadendorf Ann Silk | 2022/10/1 |
150P Phase I study of fianlimab: A human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)-Subgroup analysis | Immuno-Oncology and Technology | O Hamid K Lewis A Weise M McKean K Papadopoulos | 2022/12/1 |
